• progress_activity cloud_sync

    Reconnection to the server…

    Movim cannot talk with the server, please try again later


    • Public subscriptions

    • chevron_right

      coopr8

    • chevron_right

      gabagoo

    • chevron_right

      kenu_demon

    • chevron_right

      coopr8

    • chevron_right

      gabagoo

    • chevron_right

      kenu_demon

    • chevron_right

      coopr8

    • chevron_right

      gabagoo

    • chevron_right

      kenu_demon

  • Register Login

    Movim

    movim.chatterboxtown.us


  • group_work rss_feed
    add Follow

    ArsTechnica

    • Ar chevron_right

      Biden proposes guardrails on health care AI, upping weight-loss drug access

      news.movim.eu / ArsTechnica • 27 November 2024

    The Biden administration on Tuesday issued sweeping health care proposals that would see Medicare plans greatly expand access to blockbuster GLP-1 weight-loss drugs, bar insurers from skipping out on paying certain claims that were granted prior authorization, and reinforce guardrails on the use of AI.

    The proposals fit into the administration's existing aims to improve and protect access to care in Medicare and Medicaid programs. But, the future of the proposals is uncertain, as it will be up to the Trump administration to finalize the policies.

    Anti-obesity drugs

    The flashiest of the proposals is to reinterpret existing law in such a way as to allow Medicare and Medicaid coverage of anti-obesity drugs—particularly the extremely popular and pricy GLP-1 drugs Wegovy and Zepbound. Existing policy excludes coverage of drugs used for "weight loss" or "weight gain."

    Read full article

    Comments

    • taghealth taghealth taghealth tagpolicy tagpolicy tagpolicy tagglp-1 tagglp-1 tagglp-1 taghealthcare taghealthcare taghealthcare tagweight loss tagweight loss tagweight loss taghealth taghealth taghealth tagpolicy tagpolicy tagpolicy tagglp-1 tagglp-1 tagglp-1 taghealthcare taghealthcare taghealthcare tagweight loss tagweight loss tagweight loss taghealth taghealth taghealth tagpolicy tagpolicy tagpolicy tagglp-1 tagglp-1 tagglp-1 taghealthcare taghealthcare taghealthcare tagweight loss tagweight loss tagweight loss

    • Pictures 3 image

    • visibility
    • visibility
    • visibility
    • Ar chevron_right

      Biden proposes guardrails on health care AI, upping weight-loss drug access

      news.movim.eu / ArsTechnica • 27 November 2024

    The Biden administration on Tuesday issued sweeping health care proposals that would see Medicare plans greatly expand access to blockbuster GLP-1 weight-loss drugs, bar insurers from skipping out on paying certain claims that were granted prior authorization, and reinforce guardrails on the use of AI.

    The proposals fit into the administration's existing aims to improve and protect access to care in Medicare and Medicaid programs. But, the future of the proposals is uncertain, as it will be up to the Trump administration to finalize the policies.

    Anti-obesity drugs

    The flashiest of the proposals is to reinterpret existing law in such a way as to allow Medicare and Medicaid coverage of anti-obesity drugs—particularly the extremely popular and pricy GLP-1 drugs Wegovy and Zepbound. Existing policy excludes coverage of drugs used for "weight loss" or "weight gain."

    Read full article

    Comments

    • taghealth taghealth taghealth tagpolicy tagpolicy tagpolicy tagglp-1 tagglp-1 tagglp-1 taghealthcare taghealthcare taghealthcare tagweight loss tagweight loss tagweight loss taghealth taghealth taghealth tagpolicy tagpolicy tagpolicy tagglp-1 tagglp-1 tagglp-1 taghealthcare taghealthcare taghealthcare tagweight loss tagweight loss tagweight loss taghealth taghealth taghealth tagpolicy tagpolicy tagpolicy tagglp-1 tagglp-1 tagglp-1 taghealthcare taghealthcare taghealthcare tagweight loss tagweight loss tagweight loss

    • Pictures 3 image

    • visibility
    • visibility
    • visibility
    • Ar chevron_right

      Biden proposes guardrails on health care AI, upping weight-loss drug access

      news.movim.eu / ArsTechnica • 27 November 2024

    The Biden administration on Tuesday issued sweeping health care proposals that would see Medicare plans greatly expand access to blockbuster GLP-1 weight-loss drugs, bar insurers from skipping out on paying certain claims that were granted prior authorization, and reinforce guardrails on the use of AI.

    The proposals fit into the administration's existing aims to improve and protect access to care in Medicare and Medicaid programs. But, the future of the proposals is uncertain, as it will be up to the Trump administration to finalize the policies.

    Anti-obesity drugs

    The flashiest of the proposals is to reinterpret existing law in such a way as to allow Medicare and Medicaid coverage of anti-obesity drugs—particularly the extremely popular and pricy GLP-1 drugs Wegovy and Zepbound. Existing policy excludes coverage of drugs used for "weight loss" or "weight gain."

    Read full article

    Comments

    • taghealth taghealth taghealth tagpolicy tagpolicy tagpolicy tagglp-1 tagglp-1 tagglp-1 taghealthcare taghealthcare taghealthcare tagweight loss tagweight loss tagweight loss taghealth taghealth taghealth tagpolicy tagpolicy tagpolicy tagglp-1 tagglp-1 tagglp-1 taghealthcare taghealthcare taghealthcare tagweight loss tagweight loss tagweight loss taghealth taghealth taghealth tagpolicy tagpolicy tagpolicy tagglp-1 tagglp-1 tagglp-1 taghealthcare taghealthcare taghealthcare tagweight loss tagweight loss tagweight loss

    • Pictures 3 image

    • visibility
    • visibility
    • visibility
  • cloud_queue

    Powered by Movim